Cellebrite DI (NASDAQ:CLBT) Hits New 1-Year Low Following Insider Selling

Cellebrite DI Ltd. (NASDAQ:CLBT) hit a new 52-week low on Thursday following insider selling activity. The stock traded as low as $10.55 and last traded at $10.1960, with a volume of 908842 shares traded. The stock had previously closed at $15.25.

Specifically, CEO Thomas E. Hogan sold 139,713 shares of Cellebrite DI stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total value of $2,150,183.07. Following the transaction, the chief executive officer owned 790,548 shares of the company’s stock, valued at approximately $12,166,533.72. This trade represents a 15.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Analyst Ratings Changes

Several brokerages have commented on CLBT. Weiss Ratings cut shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. Lake Street Capital cut their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday. DA Davidson reduced their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.70.

Key Headlines Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Cellebrite DI Stock Performance

The firm’s 50 day moving average is $14.47 and its 200-day moving average is $14.03. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of 50.64, a price-to-earnings-growth ratio of 1.34 and a beta of 1.18.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The firm had revenue of $131.14 million during the quarter, compared to analysts’ expectations of $131.50 million. Cellebrite DI had a net margin of 11.43% and a return on equity of 16.04%. As a group, research analysts predict that Cellebrite DI Ltd. will post 0.41 EPS for the current year.

Institutional Trading of Cellebrite DI

Several large investors have recently made changes to their positions in the stock. Roubaix Capital LLC grew its holdings in Cellebrite DI by 108.1% during the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock valued at $4,178,000 after purchasing an additional 157,536 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Cellebrite DI in the first quarter valued at approximately $2,134,000. Principal Financial Group Inc. lifted its stake in shares of Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after buying an additional 545,334 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Cellebrite DI by 28.6% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after buying an additional 300,000 shares during the last quarter. Finally, Weiss Asset Management LP boosted its holdings in shares of Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after buying an additional 1,846,851 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.